Syros Pharmaceuticals, Inc. (SYRS) P/E Ratio History
Historical price-to-earnings valuation from 2026 to 2026
Loading P/E history...
SYRS Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Syros Pharmaceuticals, Inc. (SYRS) trades at a price-to-earnings ratio of -0.0x, with a stock price of $0.00 and trailing twelve-month earnings per share of $-2.49.
Compared to the Healthcare sector median P/E of 22.3x, SYRS trades at a 100% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, SYRS trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our SYRS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
See SYRS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SYRS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SYRS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSYRS — Frequently Asked Questions
Quick answers to the most common questions about buying SYRS stock.
Is SYRS stock overvalued or undervalued?
SYRS current P/E: -0.0x. 5-year average P/E: N/A. Percentile: N/A.
How does SYRS's valuation compare to peers?
Syros Pharmaceuticals, Inc. P/E of -0.0x compares to sector median of 22.3x. Sector comparison provides relative valuation context.
What is SYRS's PEG ratio?
SYRS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2026-2026.